BofA analyst Jason Gerberry raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $64 from $63 and keeps a Buy rating on the shares following FDA approval of Dawnzera for the treatment of hereditary angioedema. Dawnzera was approved on time with a good label in the firm’s view as the drug was approved for both every four weeks and every eight weeks dosing, and label was clean without major safety warning, BofA told investors. The firm cited un-risk adjusting Dawnzera forecast in their model as the reason behind the price target uptick.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals’ Dawnzera: A Promising New Entrant in HAE Treatment with Strong Market Potential
- Ionis Pharmaceuticals: Strategic Positioning and Revenue Potential Boost Buy Rating
- Ionis Pharmaceuticals price target raised to $43 from $38 at Stifel
- Ionis Pharmaceuticals Gains FDA Approval for DAWNZERA
- Ionis Pharmaceuticals trading resumes